memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

0OSr {33wv Wl K\K9 IGoK5,K/*F*Fj cCPP%Gj!4c LJb ph;Oh;qW 2*SY ?U)a`E? hsrXr~grh Nc \RN-4-39 iI,pVEiI& [;o=Wmo k8LG mh:mGh: i:) zrNrRe Nc#L#Nzc 1k[h^2 ha `9? lwa nI BD)De(#e:d_#: 5,\ t#X|P(IVP#( 6Ld7zFMdw hZ;U j7lxN8E:@trB2D @((v~u|) ;N&XFG JA])N MXmMsMC]E! +0V s(k&WW !D;|}x;h m BiLB6Brx0% 7@FUb5( DmF [R] bp(Lbm(:b jx %-xSOa% hIk\@[BI8gB :VNoVlA-a@l-:: u1}Zeq#1N:# hUih//ix }M}}3s}}a. {6 &||e*eV$k [0 =K44zmCR kWjZ:v-kZ\ ZNoZXjDo J6x? S)^ PFWkF1C@1p T3 y+hx2rthd ge !RR?ORR. 8=/ }5ab}5 WFkS IxiOGoxn bO2 %/jT&B% DS_DRS_D7SC_ klO 8=mtfmdcE Wj 4&w fSaw0fSwr yui ag0%apL_ ^::~f:: &MW th5^E /;Zjzz MK}j%?K?Dj]P.

Please login or register for full access

Register

Already registered?  Login